Atrogi reports early trial success for drug that cuts fat while building muscle
Atrogi announced positive human data for ATR-258 from an 8-week, investigator-initiated, open-label, single-arm study in 13 overweight or obese subjects. ATR-258 is a first-in-class, oral GRK2-biased β2-adrenergic modulator designed to target skeletal muscle and to improve body composition and muscl
<p>Atrogi announced positive human data for ATR-258 from an 8-week, investigator-initiated, open-label, single-arm study in 13 overweight or obese subjects. ATR-258 is a first-in-class, oral GRK2-biased β2-adrenergic modulator designed to target skeletal muscle and to improve body composition and muscl</p>